{‘She possesses zero experience’: this US scientific community prepares for Høeg's role at the Food and Drug Administration.

While America undertakes historic changes to its vaccination guidelines, one figure appears unexpectedly: Tracy Beth Høeg, a Danish American physician and public health researcher who initially gained attention by casting doubt on Covid vaccinations throughout the global health crisis and has focused upon potential deaths following COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Program

Agency leaders were set to unveil sweeping changes to the childhood vaccination calendar recently, synchronizing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US at odds with many the international standard with little proof for improved outcomes. The announcement has been postponed until the new year.

In place of Vinay Prasad, Dr. Høeg is listed to speak at the gathering. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to run the office this year.

A Shift at the FDA

This interim role might represent a tighter collaboration between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the agency – and it points to a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for halting some pediatric vaccine recommendations in the US in order to be more in line with Denmark, a country with universal health coverage and a citizenry about the size of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccines – usually the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Expertise

Høeg has no obvious experience in pharmaceutical research, approval processes or leadership, which has been customary for past directors of the CBER. She has been employed at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a large organization. She has no expertise in pharmaceutical oversight.”

Past directors of the center would “grasp laws and regulations and the underlying principles of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that previous people who ran CBER have had.”

CDER has an enormous portfolio at the FDA, Woodcock emphasized.

“Many people just focuses on the innovative therapies, but the generic program clears numerous generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and every single one have to be managed,” Woodcock noted. “The area you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major leadership component to the job, which supervises in excess of 5,000 staff members. “It is a enormous administrative position, if you perform it correctly,” the former official added.

Official Statement and Controversial Initiatives

In response to questions about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “inquiries are based on flawed premises”.

“Her resume matches the duties of her job,” the representative explained, citing the period Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's controversial expedited review system, a disputed rapid medication authorization process that allegedly troubled her preceding directors. “How are these medications being picked for this voucher program? Who takes the decisions?” Dr. Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

Overall, he remarked, “the agency appears to be shifting towards more relaxed regulations of pharmaceuticals, aside from immunizations.”

Documented Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if troubling, history, Howard have noted. She authored a analysis using non-validated crowd-sourced reports to determine the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccines are riskier than they are.

Included in her “desired changes” for the new government featured changing rules for recently developed shots and ending “optional” immunizations, she remarked after the election on a audio program. At the agency, Høeg has allegedly proposed barring teenage boys from obtaining COVID-19 vaccinations.

“She’s an thorough true believer who commences with her beliefs and works backwards to fit the data in a extremely disingenuous, fraudulent fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined fellow skeptics, {like|